{
  "id": "61f7ce26882a024a1000002d",
  "type": "factoid",
  "question": "Idecabtagene vicleucel can be used for treatment of which disease?",
  "ideal_answer": "Idecabtagene vicleucel was shown to be effective for Relapsed and Refractory Multiple Myeloma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34461271",
    "http://www.ncbi.nlm.nih.gov/pubmed/34256668",
    "http://www.ncbi.nlm.nih.gov/pubmed/33896344",
    "http://www.ncbi.nlm.nih.gov/pubmed/34527606",
    "http://www.ncbi.nlm.nih.gov/pubmed/34625232",
    "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
    "http://www.ncbi.nlm.nih.gov/pubmed/33598857",
    "http://www.ncbi.nlm.nih.gov/pubmed/34854741",
    "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
    "http://www.ncbi.nlm.nih.gov/pubmed/34145225"
  ],
  "snippets": [
    {
      "text": "B-cell maturation antigen (BCMA) has become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already received regulatory approval in the United States. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34461271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include isatuximab (also anti-CD38) and, in the past year, the antibody-drug conjugate (ADC) belantamab mafodotin and the chimeric antigen receptor (CAR) T-cell product idecabtagene vicleucel (ide-cel).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34527606",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256668",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVE: Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33598857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two ther",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33896344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple m",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33896344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34854741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34854741",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed an",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The bulk of CAR T-cell constructs currently in clinical development target the B-cell maturation antigen (BCMA) and to date only idecabtagene vicleucel (ide-cel) is approved by the Food and Drug Administration (FDA) for commercial use in adult patients with relapsed or refractory MM based on the promising clinical responses and positive safety record shown in the pivotal KarMMa study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34625232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Multiple Myeloma"
}